Home
About
Contact
Management
Technology
Media
Press Release 06/19/18
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
7 Hills Pharma Appoints Lionel D. Lewis As Chief Medical Officer
7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
7 Hills Pharma Receives $3.5M to Continue Development Of Integrin Activators to Augment Immunotherapies
7 Hills Pharma Highlights Cell Adhesion
7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines
7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
Opinion: Warp Speed to a united or divided America? COVID-19 vaccine trials must include at-risk groups
7 Hills Pharma to Participate in Johnson & Johnson Innovation’s BLUE KNIGHT™ Collaboration with U.S. Government for its Efforts to Combat COVID-19
BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration
7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines
7 Hill Pharma Names William Schary VP of Clinical & Regulatory Affairs
7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs COVID-19 and Influenza Vaccines
7 Hills Pharma Receives Orphan Drug Designation for Lead Product, 7HP349, in Treatment of Malignant Melanoma
7 Hills Pharma CEO Cites Seniors’ Weakened Immune Systems as Challenge for COVID-19 Vaccines’ Effectiveness
Two Incentives that Could Open the Floodgates to Drug Repositioning for COVID-19
7 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers
Scientific Advisory Board
Corporate Board
Management
Leadership
Publications
SAB - with Dr. Humphrey
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
Home
About
Contact
Management
Technology
Media
Press Release 06/19/18
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
7 Hills Pharma Appoints Lionel D. Lewis As Chief Medical Officer
7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
7 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12
7 Hills Pharma Receives $3.5M to Continue Development Of Integrin Activators to Augment Immunotherapies
7 Hills Pharma Highlights Cell Adhesion
7 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines
7 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies
Opinion: Warp Speed to a united or divided America? COVID-19 vaccine trials must include at-risk groups
7 Hills Pharma to Participate in Johnson & Johnson Innovation’s BLUE KNIGHT™ Collaboration with U.S. Government for its Efforts to Combat COVID-19
BARDA enlisting start-ups in fight against COVID-19 via JLABS collaboration
7 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines
7 Hill Pharma Names William Schary VP of Clinical & Regulatory Affairs
7 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs COVID-19 and Influenza Vaccines
7 Hills Pharma Receives Orphan Drug Designation for Lead Product, 7HP349, in Treatment of Malignant Melanoma
7 Hills Pharma CEO Cites Seniors’ Weakened Immune Systems as Challenge for COVID-19 Vaccines’ Effectiveness
Two Incentives that Could Open the Floodgates to Drug Repositioning for COVID-19
7 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers
Scientific Advisory Board
Corporate Board
Management
Leadership
Publications
SAB - with Dr. Humphrey
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
Home
About
Technology
Leadership
Management
Corporate Board
Scientific Advisory Board
Publications
Media
Contact
DEVELOPING NOVEL IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER AND THE PREVENTION OF INFECTIOUS DISEASES
View on Mobile